GlassScriptPhysician profile
Donathan Hudgins
NPI 1144206350
$3,217.52
in general payments reported to CMS, 2019-2025
9 companies · $564 in 2025
The $564 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2021: $60.99 · 2022: $1,447 · 2023: $334 · 2024: $466 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343 · Education: $20.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.82 |
| Education | $20.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,279.87 | 2021-2024 | |
| Johnson & Johnson Vision Care, INC. | $521.01 | 2023-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $473.21 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Oyster Point Pharma, INC. | $281.93 | 2022-2025 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $230.46 | 2019 | |
| Alcon Vision LLC | $216.85 | 2022 | |
| Shire North American Group INC | $115.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $82.67 | 2022 | |
| Sun Pharmaceutical Industries INC. | $16.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donathan Hudgins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.